Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer

European Journal of Surgical Oncology

Volumn 34, Issue 2, 2008, Pages 129-134

  Noguchi, M ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Axillary lymph node dissection; Breast cancer; Sentinel lymph node biopsy

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDLINE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION;

ADULT; AGED; AXILLA; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LYMPH NODE EXCISION; LYMPH NODES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38149136553     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.03.026     Document Type: Review

References (46)

1. Rubio I.T. Positive sentinel lymph node: new controversies regarding axillary node dissection. J Surg Oncol 93 (2006) 517-518
2. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., and Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 8 (2002) 567-575
3. Noguchi M., Miwa K., Michigishi T., et al. The role of axillary lymph node dissection in breast cancer management. Breast Cancer 4 (1997) 143-153
4. Greco M., Agresti R., Cascinelli N., et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg 232 (2000) 1-7
5. Fisher B., Redmond C., Fisher E.R., et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312 (1985) 674-681
6. Noguchi M., Katev N., and Miyazaki I. Diagnosis of axillary lymph node metastases in patients with breast cancer. Breast Cancer Res Treat 40 (1996) 283-293
7. Somasundar P., Gass J., Steihoff M., et al. Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer. Am J Surg 192 (2006) 458-461
8. Recht P.P., Connolly J.L., Schnitt S.J., et al. Conservative surgery and radiation therapy for early breast cancer; results, controversies, and unsolved problems. Semin Oncol 13 (1986) 434-449
9. Fisher B., Brown A., Mammounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 15 (1997) 2483-2493
10. Bonadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Onocol 16 (1998) 93-100
11. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 (1999) 72-78
12. Mamounas E.P., and Fisher B. Preoperative chemotherapy for operable breast cancer. Cancer Treat Res 103 (2000) 137-155
13. Noguchi M., Tsugawa K., Kawahara F., et al. Dye-guided sentinel lymphadenectomy in clinically node-negative and node-positive breast cancer patients. Breast Cancer 5 (1998) 381-387
14. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project B-27. J Clin Oncol 23 (2005) 2694-2702
15. Carter C.L., Allen C., and Henson D. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
16. Lang J.E., Esserman L.J., Ewing C.A., et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. Am Coll Surg 199 (2004) 856-862
17. Jones J.L., Zabicki K., Christian R.L., et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 190 (2005) 517-520
18. Schwartz G.F., Giuliano A.E., Veronesi U., et al. Proceedings of consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. April 2001, Philadelphia, PA. Hum Pathol 33 (2002) 579-589
19. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumors. 6th ed (2002), Wiley-Liss, New York
20. Adair F., Berg J., Joubert L., and Robbins G.F. Long-term follow-up of breast cancer patients; the 30-year report. Cancer 33 (1974) 1145-1150
21. Chu K.U., Turner R.R., Hansen N.M., et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?. Ann Surg 229 (1999) 536-541
22. Reynolds C., Mick R., Donohue J.H., et al. Sentinel lymph node biopsy with metastases: can axillary dissection be avoided in some patients with breast cancer?. J Clin Oncol 17 (1999) 1720-1726
23. Viale G., Maiorano E., Pruneri G., et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Am Surg 241 (2005) 319-325
24. Menes T.S., Tartter P.I., Mizrachi H., et al. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Surg 200 (2005) 323-327
25. Takei H., Suemasu K., Kurosumi M., et al. Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer 14 (2007) 16-24
26. Wong J.S., Recht A., Beard C.J., et al. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys 39 (1997) 915-920
27. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 71-85
28. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
29. White Jr. R.L., and Wilke L.G. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 70 (2004) 420-424
30. Rutgers E.J.T., Meijnen P., Bonnefoi H., et al. Clinical trial update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res Treat 6 (2004) 165-169
31. Dowlatshali K., Fan M., Snider H.C., and Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 80 (1997) 1188-1197
32. Cserni G., Gregori D., Merletti F., et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast caner. Br J Surg 91 (2004) 1245-1252
33. Viale G., Maiorano E., Mazzarol G., et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92 (2001) 1378-1384
34. den Bakker M.A., van Weeszenberg A., de Kanter A.Y., et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis: too early to abandon axillary clearance. J Clin Pathol 55 (2002) 932-935
35. Degnim A.C., Griffith K.A., Sabel M.S., et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 98 (2003) 2307-2315
36. Smidt M.L., Janssen C.M.M., Kuster D.M., et al. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12 (2005) 29-33
37. Noguchi M. Is it necessary to perform prospective randomized studies before sentinel node biopsy can replace routine axillary dissection?. Breast Cancer 10 (2003) 179-187
38. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th ed (2002), Springer-Verlag, New York (NY)
39. Singletary S.E., Greene F.L., and Sobin L.H. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on cancer staging manual. Cancer 98 (2003) 2740-2741
40. Weaver D.L. Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant?. Am J Surg Pathol 27 (2003) 842-845
41. Cserni G. Sentinel node biopsy in breast cancer and its implications for histopathological examination. Histopathology 46 (2005) 697-706
42. Katz A., Niemierko A., Gage I., et al. Can axillary dissection be avoided in patients with sentinel lymph node metastases?. J Surg Oncol 93 (2006) 550-558
43. Calhoun K.E., Hansen N.M., Turner R.R., and Giuliano A.E. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg 190 (2005) 588-591
44. Katz A., Gage I., Evans S., et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 191 (2006) 761-766
45. Lara J.F., Young S.M., Velilla R.E., Santoro E.J., and Templeton S.F. The relevance of occult axillary micrometastases in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 98 (2003) 2105-2113
46. Pendas S., Dauway E., Giuliano R., Ku N., Cox C.E., and Reintgen D.S. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 7 (2000) 15-20